Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

TPB Publications

2009 Publications

  1. Matthews, K., P.E. Noker, B. Tian, S.D. Grimes, R. Fulton, K. Schweikart, R. Harris, R. Aurigemma, M. Wang,, M.N. Barnes, G.P. Siegal , A. Hemminki, K. Zinn, D.T. Curiel, and R.D. Alvarez, 2009. Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer. Clin Cancer Res 15:4131-4137.
  2. Sanghvi, R., E. Mogalian, S.G. Machatha, R. Narazaki, K.L. Karlage, P. Jain, E.S. Tabibi, E.R. Glaze, P.B. Myrdal, and S.H. Yalkowsky, 2009. Preformulation and Pharmacokinetic Studies on Antalarmin: A Novel Stress Inhibitor. J Pharm Sci, 98(1), 205-214.
  3. Sen M, Tosca P, Zwayer C, Ryan,M, Johnson J, Knostman, K, Katherine AB, Giclas, Patricia C, Peggins, James O, Tomaszewski, JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE and Grandis JR. (2009) Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol , 63 (6), 983-95.

About the Branch Chief

For information regarding the TPB, please contact Dr. Jerry M. Collins, Associate Director, collinsje@mail.nih.gov